The fully linked HTML version of this article has now been published.
JCS ePress
online publication date 29 Mar 2005
doi: 10.1242/jcs.02308
Research Article
Activation of either ERK1/2 or ERK5 MAP kinase pathways can lead to disruption of the actin cytoskeleton
Joana Castro Barros
and
Christopher J. Marshall*
* Author for correspondence (e-mail: chris.marshall{at}icr.ac.uk)
Oncogenic transformation often leads to the disruption of the actin cytoskeleton. Activation of the classical Ras-Raf-MEK1/2-ERK1/2 signalling cascade has been implicated in the effects of oncogenes such as Ras and Src on the cytoskeleton. Many of the studies of the effects of oncogenes on the cytoskeleton have made use of chemical inhibitors of MEK1/2 but it is now clear that these inhibitors also inactivate MEK5 in the MEK5-ERK5 MAP kinase pathway raising the possibility that this pathway may also be involved in oncogenic transformation. We therefore investigated whether activation of ERK5 can lead to disruption of the actin cytoskeleton. We show that activation of ERK5 can lead to loss of actin stress fibres, but by a distinct mechanism to ERK1/2. We demonstrate that ERK5 is activated by oncogenic Src as demonstrated by translocation of endogenous ERK5 from the cytoplasm to nucleus and activation of an ERK5-dependent transcriptional reporter and that ERK5 activation is required for Src-mediated transformation. We also show that in Src-transformed cells inhibition of ERK1/2 signalling is not sufficient for reappearance of the actin cytoskeleton and that ERK5 activation contributes to cytoskeletal disruption by Src. Our results suggest that multiple MAP kinase pathways downstream of oncogenes participate in cytoskeletal alterations.
This article has been cited by other articles:

|
 |

|
 |
 
J. Park, C. Will, B. Martin, L. Gullotti, N. Friedrichs, R. Buettner, H. Schneider, S. Ludwig, and V. Wixler
Deficiency in the LIM-only protein FHL2 impairs assembly of extracellular matrix proteins
FASEB J,
July 1, 2008;
22(7):
2508 - 2520.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Schramp, O. Ying, T. Y. Kim, and G. S. Martin
ERK5 promotes Src-induced podosome formation by limiting Rho activation
J. Cell Biol.,
June 30, 2008;
181(7):
1195 - 1210.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. de Martimprey, J.-R. Bertrand, A. Fusco, M. Santoro, P. Couvreur, C. Vauthier, and C. Malvy
siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma
Nucleic Acids Res.,
January 17, 2008;
36(1):
e2 - e2.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. W. Truman, S. H. Millson, J. M. Nuttall, V. King, M. Mollapour, C. Prodromou, L. H. Pearl, and P. W. Piper
Expressed in the Yeast Saccharomyces cerevisiae, Human ERK5 Is a Client of the Hsp90 Chaperone That Complements Loss of the Slt2p (Mpk1p) Cell Integrity Stress-Activated Protein Kinase
Eukaryot. Cell,
November 1, 2006;
5(11):
1914 - 1924.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. E. Schweppe, T. H. Cheung, and N. G. Ahn
Global Gene Expression Analysis of ERK5 and ERK1/2 Signaling Reveals a Role for HIF-1 in ERK5-mediated Responses
J. Biol. Chem.,
July 28, 2006;
281(30):
20993 - 21003.
[Abstract]
[Full Text]
[PDF]
|
 |
|
© The Company of Biologists Ltd 2005